SCHEMBL24780602

SCHEMBL24780602

CCCC(C)c1cc(C(F)(F)F)ccc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 4/20 0.49
NPSR1 Q6W5P4 1/20 0.42
KCNH2 Q12809 4/20 0.42
SLC6A4 P31645 2/20 0.42
HTR2A P28223 1/20 0.42
TMEM97 Q5BJF2 3/20 0.41
SLC6A2 P23975 1/20 0.40
CACNA1F O60840 1/20 0.40
CACNA1D Q01668 1/20 0.40
SLC6A3 Q01959 1/20 0.40
CACNA1S Q13698 1/20 0.40
CACNA1C Q13936 1/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2D6 P10635 2/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
HSP90AA1 P07900 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
MEN1 O00255 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18638207 0.87 PDE2A (0.61) PDE2ANPSR1KCNH2TMEM97CACNA1F
SCHEMBL14315639 0.87 PDE2A (0.51) PDE2ANPSR1KCNH2SLC6A4HTR2A
SCHEMBL26464737 0.80 PDE2A (0.45) PDE2ASLC6A4HTR2ACYP2D6LMNA
SCHEMBL12735210 0.80 PDE2A (0.50) PDE2ANPSR1KCNH2SLC6A4HTR2A
SCHEMBL12015778 0.79 PDE2A (0.58) PDE2AKCNH2SLC6A4HTR2ATMEM97
SCHEMBL20090930 0.79 PDE2A (0.59) PDE2ASLC6A4HTR2ASLC6A2SLC6A3
SCHEMBL22193303 0.78 PDE2A (0.58) PDE2AKCNH2TMEM97CACNA1FCACNA1D
SCHEMBL22004342 0.78 TP53 (0.41) NPSR1CYP3A4LMNAMEN1KMT2A
SCHEMBL21316580 0.77 PDE2A (0.49) PDE2ANPSR1KCNH2SLC6A4HTR2A
SCHEMBL22930904 0.76 PDE2A (0.54) PDE2AKCNH2SLC6A4HTR2ATMEM97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220402869-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402869-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF TEAD1, TEAD4, TEAD2 PDE2A 4199/4885NPSR1 4314/4885KCNH2 4710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.